<DOC>
	<DOCNO>NCT00915564</DOCNO>
	<brief_summary>The purpose study evaluate effect steady-state ( constant concentration medication blood ) TMC435 ( 150 mg , day ) steady state pharmacokinetics ( body medication ) R- S-methadone .</brief_summary>
	<brief_title>A Study Investigate Potential Pharmacokinetic Interaction Between TMC435 Methadone</brief_title>
	<detailed_description>This open label ( people know identity intervention ) drug-drug interaction ( TMC435 versus methadone ) study . Approximately 12 hepatitis C virus-negative opioid-dependent participant stable maintenance therapy ( least 30 day screen ) enrol study . The study consist 3 phase : 1 ) Run-in phase : phase , participant take individualize ( dose methadone adjust participant range 30 150 mg daily ) dose methadone Day -14 ( 14 day first intake TMC435 ) till Day -1 ( 1 day first intake TMC435 ) , supervise medical staff . 2 ) 7 day treatment phase : phase , participant take 150 mg dose TMC435 daily Day 1 Day 7 orally ( mouth ) plus individualized dose methadone supervise medical staff . 3 ) Follow-up phase : phase , participant continue take individualize dose methadone 30-32 day . Safety evaluation include assessment adverse event , clinical laboratory test , cardiovascular safety , physical examination alcohol breath test . The total study duration 22 day exclude screen follow-up phase .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Simeprevir</mesh_term>
	<mesh_term>Methadone</mesh_term>
	<criteria>Receiving daily oral methadone maintenance therapy stable individualize dose 30 130 mg daily least 30 day prior screen Agreeing change current methadone dose screen Day7 include daily observe document methadone intake Day14 Day8 daily observe documented TMC435 intake Day1 Day 7 Having obtain approval his/her addiction physician participation trial addiction physician agree provide medical care volunteer discharge test facility No female childbearing potential , except use effective birth control method trial least 30 day end treatment period No positive test drug abuse No positive test Hepatitis A , B C HIV1 2 Impaired liver disease clinically relevant disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>HCV</keyword>
	<keyword>Hepatitis C Virus</keyword>
	<keyword>HCV negative</keyword>
	<keyword>Protease inhibitor</keyword>
	<keyword>Methadone</keyword>
	<keyword>TMC435</keyword>
</DOC>